Influvac Tetra

B/Phuket/3073/2013‑Like Virus (B/Phuket/3073/2013, Wild Type) and Influenza Virus B/Austria/1359417/202, the active ingredients in Influvac Tetra, are influenza virus vaccine components presented as an injectable formulation for intramuscular or subcutaneous use. They stimulate immune protection against seasonal influenza strains in children and adults.

GNH USA supplies Influvac Tetra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Influvac Tetra is indicated for the prevention of influenza infection, targeting the seasonal influenza virus family.

- Seasonal influenza: reduces the incidence of flu illness in eligible populations. - Influenza B/Yamagata lineage (B/Phuket): provides immune protection against the B/Phuket strain. - Influenza B/Victoria lineage (B/Austria): provides immune protection against the B/Austria strain.

Administration of Influvac Tetra may be associated with local and systemic reactions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: transient erythema or edema around the injection area. - Fever: low‑grade temperature elevation within 24‑48 hours. - Headache: mild headache occurring shortly after vaccination. - Myalgia: muscle aches commonly reported in the days following injection. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder potentially linked to vaccination. - Severe allergic reaction: urticaria, angioedema, or respiratory distress. - Seizures: uncommon neurologic events post‑vaccination. - High fever: temperature >40°C persisting beyond 48 hours. - Thrombocytopenia: rare drop in platelet count.

Before administering Influvac Tetra, consider the following precautions.

- Allergy screening: verify no severe allergy to egg protein or vaccine components. - Acute illness: postpone vaccination in individuals with moderate or severe febrile illness. - Immunocompromised patients: assess risk‑benefit as response may be reduced. - Concomitant vaccines: separate administration of live vaccines by at least 4 weeks. - Pregnancy and lactation: discuss potential benefits and limited data with the prescriber. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvac Tetra may interact with other therapies; monitor accordingly.

Major Interactions (Avoid): - Live attenuated vaccines: concurrent use can interfere with immune response. - Immunoglobulin therapy: may diminish vaccine‑induced immunity.

Moderate Interactions (Monitor Closely): - Antipyretics (e.g., acetaminophen): may mask fever, affecting post‑vaccination monitoring. - Antiviral medications (e.g., oseltamivir): could alter immune response if started shortly before vaccination. - Immunosuppressive drugs: may reduce vaccine efficacy, requiring timing adjustments. - Corticosteroids (systemic): monitor for attenuated antibody production.